Gene encoding EGFR is amplified in approximately 50% of GB patients, and in 50–60% of cases, amplification is accompanied by EGFRvIII expression that is tumor cell-specific, making this oncogenic protein a perfect therapeutic target [22, 31, 32]. Here, EGFR is linked to neoplasm.